HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by M. McKinney, D. Articles by Mosier, D. E. Search for Related Content PubMed PubMed Citation Articles by M. McKinney, D. Articles by Mosier, D. E. Pubmed/NCBI databases Substance via MeSH

The Antiviral Activity of HIV-Specific CD8⁺ CTL Clones Is Limited by Elimination Due to Encounter with HIV-Infected Targets¹

Denise M. McKinney^*, Deborah A. Lewinsohn, Stanley R. Riddell, Philip D. Greenberg and Donald E. Mosier^2,*

^* Department of Immunology, Scripps Research Institute, La Jolla, CA 92037; and Program in Immunology, Fred Hutchinson Cancer Research Center, and Departments of Medicine and Immunology, University of Washington, Seattle, WA 98195

Adoptive immunotherapy of virus infection with viral-specific CTL has shown promise in animal models and human virus infections and is being evaluated as a therapy for established HIV-1 infection. Defining the individual obstacles for success is difficult in human trials. We have therefore examined the localization, persistence, and antiviral activity of HIV-1 gag-specific CTL clones in both HIV-1-infected and uninfected haplotype-matched human (hu)-PBL-SCID mice. Injection of gag-specific clones but not control CTL into HIV-1-infected hosts reduced plasma viremia by >10-fold but failed to eliminate the virus infection from most treated animals. The failure to eradicate virus did not reflect selection of escape variants because the gag epitope remained unmutated in virus isolates obtained after CTL therapy. Injection of carboxyfluorescein diacetate succinimide ester-labeled CTL demonstrated markedly different fates for gag-specific CTL in the presence or absence of HIV-1 infection. HIV-1-specific CTL rapidly disappeared in infected recipients, whereas they were maintained at high numbers in uninfected mice. By contrast, control CTL were long lived in both infected and uninfected recipients. Thus, interaction of CTL with virus-infected target cells in vivo leads not only to target destruction but also to the rapid disappearance of the infused CTL, and it limits the capacity of CTL therapy to eliminate HIV-1 infection.

This article has been cited by other articles:

				W. D. Wick, O. O. Yang, L. Corey, and S. G. Self How Many Human Immunodeficiency Virus Type 1-Infected Target Cells Can a Cytotoxic T-Lymphocyte Kill? J. Virol., November 1, 2005; 79(21): 13579 - 13586. [Abstract] [Full Text] [PDF]

				S. Gorantla, K. Santos, V. Meyer, S. Dewhurst, W. J. Bowers, H. J. Federoff, H. E. Gendelman, and L. Poluektova Human Dendritic Cells Transduced with Herpes Simplex Virus Amplicons Encoding Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Elicit Adaptive Immune Responses from Human Cells Engrafted into NOD/SCID Mice and Confer Partial Protection against HIV-1 Challenge J. Virol., February 15, 2005; 79(4): 2124 - 2132. [Abstract] [Full Text] [PDF]

				L. S. Weinberger, D. V. Schaffer, and A. P. Arkin Theoretical Design of a Gene Therapy To Prevent AIDS but Not Human Immunodeficiency Virus Type 1 Infection J. Virol., September 15, 2003; 77(18): 10028 - 10036. [Abstract] [Full Text] [PDF]

				S. Venturini, D. E. Mosier, D. R. Burton, and P. Poignard Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Gag- and Gag Peptide-Specific CD4+ T-Cell Clones from an HIV-1-Seronegative Donor following In Vitro Immunization J. Virol., June 14, 2002; 76(14): 6987 - 6999. [Abstract] [Full Text] [PDF]

				S. Imlach, S. McBreen, T. Shirafuji, C. Leen, J. E. Bell, and P. Simmonds Activated Peripheral CD8 Lymphocytes Express CD4 In Vivo and Are Targets for Infection by Human Immunodeficiency Virus Type 1 J. Virol., December 1, 2001; 75(23): 11555 - 11564. [Abstract] [Full Text]

				C. L. Day, A. K. Shea, M. A. Altfeld, D. P. Olson, S. P. Buchbinder, F. M. Hecht, E. S. Rosenberg, B. D. Walker, and S. A. Kalams Relative Dominance of Epitope-Specific Cytotoxic T-Lymphocyte Responses in Human Immunodeficiency Virus Type 1-Infected Persons with Shared HLA Alleles J. Virol., July 15, 2001; 75(14): 6279 - 6291. [Abstract] [Full Text]

				R. E. Walker, C. M. Bechtel, V. Natarajan, M. Baseler, K. M. Hege, J. A. Metcalf, R. Stevens, A. Hazen, R. M. Blaese, C. C. Chen, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection Blood, July 15, 2000; 96(2): 467 - 474. [Abstract] [Full Text] [PDF]